A FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 events from 2003 to 2024. The strongest signals were for cidofovir and rifabutin, and the findings were described as hypothesis-generating rather than causal.
BioVersys AG received FDA approval to enroll U.S. patients in a global Phase 3 trial evaluating BV100 for hospital-acquired pneumonia caused by carbapenem-resistant Acinetobacter baumannii, with trial completion expected by end of 2027.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07514364 |
The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance |
RECRUITING | PHASE4 |
| NCT04310930 |
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment |
RECRUITING | PHASE2/PHASE3 |
